Ubs Group Ag Sangamo Therapeutics, Inc Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Sangamo Therapeutics, Inc stock. As of the latest transaction made, Ubs Group Ag holds 98,170 shares of SGMO stock, worth $119,767. This represents 0.0% of its overall portfolio holdings.

Number of Shares

98,170

Previous 85,214 15.2%

Holding current value

$119,767

Previous $30,000 180.0%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.32 - $1.1 $4,145 - $14,251	12,956 Added 15.2%	98,170 $84,000
Q2 2024 Aug 13, 2024	SELL	$0.36 - $0.65 $27,030 - $48,805	-75,086 Reduced 46.84%	85,214 $30,000
Q1 2024 May 13, 2024	BUY	$0.42 - $1.38 $7,606 - $24,993	18,111 Added 12.74%	160,300 $107,000
Q4 2023 Feb 09, 2024	SELL	$0.3 - $0.63 $181,137 - $380,388	-603,791 Reduced 80.94%	142,189 $76,000
Q3 2023 Nov 09, 2023	BUY	$0.58 - $1.47 $376,497 - $954,225	649,133 Added 670.27%	745,980 $447,000
Q2 2023 Aug 11, 2023	SELL	$1.11 - $1.74 $189,550 - $297,132	-170,766 Reduced 63.81%	96,847 $125,000
Q1 2023 May 12, 2023	SELL	$1.66 - $3.67 $538,572 - $1.19 Million	-324,441 Reduced 54.8%	267,613 $470,000
Q4 2022 Feb 08, 2023	BUY	$2.77 - $5.07 $1.35 Million - $2.46 Million	485,785 Added 457.13%	592,054 $1.86 Million
Q3 2022 Nov 10, 2022	SELL	$4.27 - $6.39 $390,051 - $583,707	-91,347 Reduced 46.22%	106,269 $520,000
Q2 2022 Aug 10, 2022	SELL	$3.28 - $6.21 $861,865 - $1.63 Million	-262,764 Reduced 57.08%	197,616 $818,000
Q1 2022 May 16, 2022	BUY	$5.23 - $7.82 $271,792 - $406,389	51,968 Added 12.72%	460,380 $2.68 Million
Q4 2021 Feb 14, 2022	BUY	$7.29 - $10.97 $864,280 - $1.3 Million	118,557 Added 40.9%	408,412 $3.06 Million
Q3 2021 Nov 15, 2021	BUY	$9.01 - $12.01 $1.57 Million - $2.1 Million	174,571 Added 151.43%	289,855 $2.61 Million
Q2 2021 Aug 13, 2021	SELL	$10.17 - $12.64 $2.34 Million - $2.91 Million	-230,444 Reduced 66.65%	115,284 $1.38 Million
Q1 2021 May 12, 2021	BUY	$10.88 - $17.05 $3.34 Million - $5.23 Million	306,841 Added 789.06%	345,728 $4.33 Million
Q4 2020 Feb 11, 2021	BUY	$9.23 - $18.18 $246,671 - $485,860	26,725 Added 219.74%	38,887 $607,000
Q3 2020 Nov 12, 2020	SELL	$9.38 - $12.48 $1.29 Million - $1.72 Million	-137,934 Reduced 91.9%	12,162 $115,000
Q2 2020 Jul 31, 2020	BUY	$6.21 - $11.83 $784,347 - $1.49 Million	126,304 Added 530.87%	150,096 $1.35 Million
Q1 2020 May 01, 2020	BUY	$5.05 - $8.85 $31,900 - $55,905	6,317 Added 36.15%	23,792 $151,000
Q4 2019 Feb 14, 2020	SELL	$8.03 - $11.7 $1.27 Million - $1.85 Million	-158,242 Reduced 90.06%	17,475 $147,000
Q3 2019 Nov 14, 2019	BUY	$9.05 - $12.22 $696,053 - $939,864	76,912 Added 77.84%	175,717 $1.59 Million
Q2 2019 Aug 14, 2019	BUY	$8.75 - $13.03 $691,740 - $1.03 Million	79,056 Added 400.3%	98,805 $1.06 Million
Q1 2019 May 14, 2019	SELL	$7.72 - $12.81 $2.38 Million - $3.95 Million	-308,410 Reduced 93.98%	19,749 $188,000
Q4 2018 Feb 14, 2019	BUY	$9.51 - $16.6 $2.04 Million - $3.57 Million	214,906 Added 189.76%	328,159 $3.77 Million
Q3 2018 Nov 14, 2018	BUY	$13.05 - $19.05 $478,804 - $698,944	36,690 Added 47.92%	113,253 $1.92 Million
Q2 2018 Aug 14, 2018	SELL	$13.9 - $19.8 $1.84 Million - $2.62 Million	-132,181 Reduced 63.32%	76,563 $1.09 Million
Q1 2018 May 15, 2018	BUY	$16.7 - $26.35 $3.31 Million - $5.22 Million	198,017 Added 1845.97%	208,744 $3.97 Million
Q4 2017 Feb 14, 2018	SELL	$11.6 - $17.35 $29,777 - $44,537	-2,567 Reduced 19.31%	10,727 $176,000
Q3 2017 Nov 14, 2017	SELL	$8.4 - $15.0 $145,017 - $258,960	-17,264 Reduced 56.5%	13,294 $200,000
Q2 2017 Aug 14, 2017	BUY	N/A	23,708 Added 346.1%	30,558 $269,000
Q1 2017 Nov 14, 2017	BUY	N/A	6,850	6,850 $36,000

Others Institutions Holding SGMO

# of Institutions

115

Shares Held

56.4M

Call Options Held

576K

Put Options Held

1.17M

View Full List

About SANGAMO THERAPEUTICS, INC

Ticker SGMO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 156,552,992
Market Cap $191M
Description
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...

More about SGMO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account